HC-T6IV
Hayflick Partners
topical rapamycin, mTOR inhibition, micro-dose delivery
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companies
topical rapamycin, mTOR inhibition, micro-dose delivery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Hayflick Partners topical rapamycin, mTOR inhibition, micro-dose delivery
Hayflick Therapeutics is a development-stage biotechnology company advancing rapamycin through localized, micro-dose delivery. The company is positioned at the intersection of aesthetics and healthspan and targets the mTOR pathway for cellular aging intervention. Its platform is described as patent-protected, measurable, designed for FDA approval, and focused on avoiding systemic exposure.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Hayflick Partners — Far from goals · Bottom quartile. Derived deterministically from 4 extracted project(s). Most-advanced status: undisclosed. Band: far. Modifiers: +5 depth (2 programs at undisclosed).…
Source: Deterministic